Immunic, Inc. is a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis. IMU-856 targets gastrointestinal diseases including celiac disease and IBD via SIRT6 modulation. IMU-381 is a preclinical next-generation Nurr1 platform program. The company has no approved products and operates primarily from New York and Gräfelfing, Germany.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001280776-26-000005 | EDGAR | 81K words |
| 2025-03-31 | 2024-12-31 | 0001280776-25-000005 | EDGAR | 68K words |
| 2024-02-22 | 2023-12-31 | 0001280776-24-000004 | EDGAR | 67K words |
| 2023-02-23 | 2022-12-31 | 0001280776-23-000004 | EDGAR | 76K words |
| 2022-02-24 | 2021-12-31 | 0001280776-22-000006 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001280776-21-000009 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001280776-20-000009 | EDGAR | — |
| 2019-03-04 | 2018-12-31 | 0001280776-19-000025 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001280776-18-000013 | EDGAR | — |
| 2017-03-07 | 2016-12-31 | 0001280776-17-000010 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001280776-26-000018 | EDGAR | 31K words |
| 2025-11-13 | 2025-09-30 | 0001280776-25-000017 | EDGAR | 29K words |
| 2025-08-07 | 2025-06-30 | 0001280776-25-000012 | EDGAR | 28K words |
| 2025-05-15 | 2025-03-31 | 0001280776-25-000008 | EDGAR | 22K words |
| 2024-11-07 | 2024-09-30 | 0001280776-24-000018 | EDGAR | 23K words |
| 2024-08-08 | 2024-06-30 | 0001280776-24-000014 | EDGAR | 22K words |
| 2024-05-08 | 2024-03-31 | 0001280776-24-000009 | EDGAR | 20K words |
| 2023-11-14 | 2023-09-30 | 0001280776-23-000018 | EDGAR | 24K words |
| 2023-08-03 | 2023-06-30 | 0001280776-23-000013 | EDGAR | 22K words |
| 2023-05-11 | 2023-03-31 | 0001280776-23-000010 | EDGAR | 21K words |
| 2022-11-03 | 2022-09-30 | 0001280776-22-000021 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001280776-22-000017 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-11 | 0001193805-26-001219 | EDGAR | 1K words |
| 2026-09-09 | 0001193805-26-001196 | EDGAR | 0K words |
| 2026-08-11 | 0001193805-26-001071 | EDGAR | 4K words |
| 2026-07-14 | 0001193805-26-000966 | EDGAR | 0K words |
| 2026-04-01 | 0001193805-26-000382 | EDGAR | 1K words |
| 2026-03-31 | 0001193805-26-000370 | EDGAR | 1K words |
| 2026-02-26 | 0001193805-26-000181 | EDGAR | 3K words |
| 2026-02-13 | 0001193805-26-000129 | EDGAR | 2K words |
| 2026-01-06 | 0001193805-26-000011 | EDGAR | 1K words |
| 2026-01-05 | 0001193805-26-000007 | EDGAR | 8K words |
276 total filings indexed. 244 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001280776 |
| Ticker | IMUX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | New York City, New York |
| Website | https://www.imux.com |
| Listed | 2014-04-17 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IMUX (~200 tokens, structured JSON with cryptographic provenance)